Compare Stryker's push into surgical robotics with a curated field of peers that also lean on advanced tech by scanning the 91 robotics and automation stocks for potential breakout candidates.
To own Stryker, you typically need to believe in a defensive medtech story built on procedure demand, robotics adoption and steady margin work rather than big swings. According to duarte_EM, an investor in the Simply Wall St Community, the appeal sits in Mako expansion, recurring consumables and bolt on deals supported by an ageing population. The recent quarter showed 10.3% adjusted EPS growth from margin gains and cost control, which keeps that thesis intact.
In the short term, the key swing factor looks like execution in robotics and MedSurg while working through softer hip and knee procedures plus supply bottlenecks. Cyber and SAP related disruption, together with high debt and recent insider selling, remain operational and sentiment risks. The latest robotics updates and profit momentum do not remove those issues, but they show the current playbook still working.
The appointment of James E. Davis to Stryker’s board from January 2027 is the most relevant fresh announcement here. He brings CEO experience from Quest Diagnostics, previous leadership at InSightec, and two decades across General Electric’s healthcare and aviation arms, including running the MRI business. That background sits close to Stryker’s mix of capital equipment, software and hospital customers.
This board addition intersects directly with the firm’s catalysts around robotics, smart beds and MedSurg technology. duarte_EM argues the story leans on disciplined M&A, recurring consumables and a defensive growth profile, and Davis’ track record across diagnostics and medical devices may help oversight of those execution priorities. For investors watching governance, his arrival adds another experienced voice to an already seasoned and largely independent board.
Using revenue growth of 8.0% a year and a future profit margin of 14.4%, the narrative from duarte_EM arrives at a fair value of $311.21 for Stryker by assuming the business can compound earnings at that pace while maintaining what is viewed as a quality medtech profile.
Uncover why Stryker's fair value is essentially in line with its current price.
Some analysts see Stryker very differently. Where the baseline leans on steady robotics and MedSurg execution, the most pessimistic voices focus on peripheral vascular supply problems and legal overhangs. Those forecasts had revenue at about US$31.8b and earnings near US$6.5b by 2029, yet still supported one of the lowest price targets. You can treat this board appointment as a fresh data point that may shift those views, and you can compare several narratives before deciding what makes sense for you.
Explore 5 other Stryker fair value estimates, including one that suggests it could be worth just $311.21.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
If Stryker's mix of medical technology, recurring revenue and resilient demand appeals to you, it can help to line it up against other opportunities with clear financial traits and different risk profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com